arrow
L

Luigia Stefania Stucci

university campus bio-medico
H指数:28
被引数:2,701

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases

CDK4/6抑制剂在HR+/HER2-骨转移性乳腺癌患者中的真实世界无进展生存比较

2026-05-010
OA
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis

化疗剂量强度对接受帕博利珠单抗治疗的早期三阴性乳腺癌病理完全缓解的影响:一项真实世界多中心分析

2025-11-020
OAAI
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regions

跨学科讨论:来自意大利南部地区专家小组关于转移性乳腺癌表型特征及患者路径优化的讨论

2025-05-080
PRE
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

生命晚期的PD-1/PD-L1检查点抑制剂: 来自大型多中心队列的临时分析

2021-06-2415
OAAI
Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial
2021-06-0423
OAAI
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
2021-01-0183
PREAI
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
2020-11-05161
OAAI
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
2020-09-1518
OAAI
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
2020-07-0151
OAAI